Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • FROM THE ANALYST'S COUCH

Cancer cell therapies: the clinical trial landscape

  1. Jia Xin Yu

    1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Samik Upadhaya

    1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Revati Tatake

    1. GlobalData, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Fern Barkalow

    1. GlobalData, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  5. Vanessa M. Hubbard-Lucey

    1. Anna-Maria Kellen Clinical Accelerator, Cancer Research Institute, New York, NY, USA.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Cell therapies constitute the largest number of agents in development in immuno-oncology (Nat. Rev. Drug Discov. 18, 899–900; 2019). Here, we provide an update on the pipeline and clinical trials of cancer cell therapies. We also compare the current landscape (with a March 2020 data cut-off point) with our previous update from March 2019 (Nat. Rev. Drug Discov. 18, 821–822; 2019).

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Nature Reviews Drug Discovery 19, 583-584 (2020)

doi: https://doi.org/10.1038/d41573-020-00099-9

Supplementary Information

  1. Supplementary Figures

Competing Interests

V.M.H.-L is a scientific advisor and has equity interest in Fx Biopharma. The other authors declare no competing interests.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links